Standard BioTools Analyst Price Targets - Benzinga

Standard BioTools Inc

LABNASDAQ

Trade with Public

Trade with Public

$0.6170

0.00090.15%

Últ. Act.: Oct 28, 9:21 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Standard BioTools Analyst Price Targets

Wall Street analyst price targets and consensus rating for Standard BioTools (LAB).

Price Target Range — 4 Quarters

Analyst Consensus — 2 Analysts

1Buy

1Hold

Consensus RatingBuy# Analysts2Avg. Consensus PT$2Upside to Avg. PT+285.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 5, 2025	TD Cowen	Kyle Boucher	PT Cut	Hold	$2→$1
Feb 27, 2025	Keybanc	Paul Knight	Downgrade	Overweight→Sector Weight	—
Oct 31, 2024	TD Cowen	Daniel Brennan	PT Cut	Buy	$3→$3
Aug 1, 2024	TD Cowen	Daniel Brennan	PT Cut	Buy	$4→$3
Apr 16, 2024	TD Cowen	Daniel Brennan	Initiate	Buy	$4
Apr 4, 2024	Jefferies	Matthew Stanton	Initiate	Buy	$3

Analyst Ratings News

PRO
TD Cowen Maintains Hold on Standard BioTools, Lowers Price Target to $1.35

TD Cowen analyst Kyle Boucher maintains Standard BioTools (NASDAQ:LAB) with a Hold and lowers the price target from $1.55 to $1.35.

Benzinga Newsdesk

PRO
Keybanc Downgrades Standard BioTools to Sector Weight

Keybanc analyst Paul Knight downgrades Standard BioTools (NASDAQ:LAB) from Overweight to Sector Weight.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Standard BioTools, Lowers Price Target to $2.5

TD Cowen analyst Daniel Brennan maintains Standard BioTools (NASDAQ:LAB) with a Buy and lowers the price target from $2.75 to $2.5.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Standard BioTools, Lowers Price Target to $2.75

TD Cowen analyst Daniel Brennan maintains Standard BioTools (NASDAQ:LAB) with a Buy and lowers the price target from $3.5 to $2.75.

Benzinga Newsdesk

5 Medical Info Systems Stock to Buy for a Stable Portfolio

The medical info systems industry is set to thrive in the second half of 2024 due to the growing demand for contactless services. The industry witnessed exponential growth during the pandemic era. Even in the post-pandemic period, remote healthcare, a paperless environment and distant treatment paved the way for digital services.

Zacks

PRO
TD Cowen Initiates Coverage On Standard BioTools with Buy Rating, Announces Price Target of $3.5

TD Cowen analyst Daniel Brennan initiates coverage on Standard BioTools (NASDAQ:LAB) with a Buy rating and announces Price Target of $3.5.

Benzinga Newsdesk